Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-B0396 |
Brand: | MCE |
CAS: | 161715-24-8 |
MDL | MFCD17215369 |
---|---|
Molecular Weight | 497.63 |
Molecular Formula | C22H31N3O6S2 |
SMILES | O=C(C(N1C2=O)=C(SC3CN(C4=NCCS4)C3)[C@H](C)[C@]1([H])[C@@]2([H])[C@H](O)C)OCOC(C(C)(C)C)=O |
Tebipenem pivoxil (L084) is an orally active antibiotic against a variety of pathogenic bacteria . Tebipenem pivoxil binds penicillin-binding protein (PBP), thereby inhibiting cell wall synthesis [1] .
Tebipenem pivoxil (0-128 μg/mL; 18–24 h) displays excellent antibacterial activity against a variety of pathogenic bacteria [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
Cell Line: | Gram-positive and Gram-negative bacteria |
Concentration: | 0-128 μg/mL |
Incubation Time: | 18–24 h |
Result: | Showed inhibition with MIC 50 s below 64 μg/mL against tested Gram-positive and Gram-negative bacteria. |
Tebipenem pivoxil (L084) (0-4.00 g/kg; p.o.; once) shows minimal lethal dosage (MLD) of 4.00 g/kg and the maximum tolerance dosage (MTD) of 3.40 g/kg in mice
[1]
.
Tebipenem pivoxil (50 and 100 mg/kg; p.o.; once) significantly protects the sepsis mice challenged with various pathogenic bacteria
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | KM mice weighing 18–22 g [1] |
Dosage: | 2.89, 3.40 and 4.00 g/kg |
Administration: | Oral administration (tablet), once |
Result: | Within the 14-day observation period, only one mouse was dead in the maximum oral dosage (4.00 g/kg). The minimal lethal dosage (MLD) was 4.00 g/kg and the maximum tolerance dosage (MTD) in the mice was 3.40 g/kg. Showed dose-dependent liver and kidney damage. |
Animal Model: | ICR mice, sepsis mouse models [1] |
Dosage: | 50 and 100 mg/kg |
Administration: | Oral administration (tablet), once |
Result: | Significantly increased the survival number of the sepsis mice within a 168 h observation period. |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT04238195 | Spero Therapeutics|Celerion |
TQT Study
|
January 19, 2020 | Phase 1 |
NCT04178577 | Spero Therapeutics |
Renal Impairment
|
December 6, 2019 | Phase 1 |
NCT04919954 | Hartford Hospital|Spero Therapeutics Inc |
Diabetes|Wound Infection|ABSSSI|Healthy Volunteers
|
July 1, 2021 | Phase 1 |
NCT05121974 | International Centre for Diarrhoeal Disease Research, Bangladesh|University of Washington|GlaxoSmithKline |
Shigellosis
|
August 2022 | Phase 2 |
NCT04421885 | Spero Therapeutics |
Healthy Volunteers
|
June 1, 2020 | Phase 1 |
NCT04368585 | Spero Therapeutics |
Healthy Volunteers
|
July 1, 2020 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 200 mg/mL ( 401.91 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.0095 mL | 10.0476 mL | 20.0953 mL |
5 mM | 0.4019 mL | 2.0095 mL | 4.0191 mL |
10 mM | 0.2010 mL | 1.0048 mL | 2.0095 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.